0000000000877494

AUTHOR

K Döhner

showing 3 related works from this author

Impact of pretreatment characteristics and salvage strategy on outcome in patients with relapsed acute myeloid leukemia

2017

Impact of pretreatment characteristics and salvage strategy on outcome in patients with relapsed acute myeloid leukemia

OncologyAdultMaleCancer Researchmedicine.medical_specialtyMyeloidAdolescentmedicine.medical_treatmentSalvage therapyHematopoietic stem cell transplantationOutcome (game theory)03 medical and health sciencesYoung Adult0302 clinical medicineText miningRecurrencehemic and lymphatic diseasesInternal medicineAntineoplastic Combined Chemotherapy ProtocolsmedicineHumansYoung adultLetter to the EditorAgedAged 80 and overSalvage Therapybusiness.industryHematopoietic Stem Cell TransplantationMyeloid leukemiaHematologyMiddle Agedmedicine.diseasePrognosisLeukemiaLeukemia Myeloid Acutemedicine.anatomical_structureTreatment OutcomeOncology030220 oncology & carcinogenesisFemalebusiness030215 immunologyLeukemia
researchProduct

Condensed Versus Standard Schedule of High-Dose Cytarabine Consolidation Therapy with Pegfilgrastim Growth Factor Support in Acute Myeloid Leukemia

2017

Abstract Background: The concept of intensive post-remission chemotherapy in acute myeloid leukemia (AML) is based on the observation that despite achievement of a first complete remission (CR) after intensive induction therapy virtually all patients relapse in the absence of further treatment. Moreover, randomized studies showed that intensive post-remission consolidation chemotherapy was superior to prolonged low-dose maintenance therapy in younger patients. With regard to consolidation therapy, the landmark study conducted by the Cancer and Leukemia Group B established the current standard for patients aged 60 years and younger with high-dose cytarabine (HDAC) 3g/m² bidaily on days days …

MaleOncologymedicine.medical_treatmentHematopoietic stem cell transplantationGastroenterologyBiochemistryPolyethylene Glycols0302 clinical medicineMaintenance therapyAntineoplastic Combined Chemotherapy ProtocolsMedicineCytarabineMyeloid leukemiaHematologyMiddle AgedChemotherapy regimen3. Good healthSurvival RateLeukemia Myeloid AcuteLeukemiaOncology030220 oncology & carcinogenesisOriginal ArticleFemalePegfilgrastimmedicine.drugAdultmedicine.medical_specialtyAdolescentFilgrastimImmunologyPlatelet TransfusionFilgrastimDisease-Free Survival03 medical and health sciencesInternal medicineHumansIdarubicinSurvival rateChemotherapybusiness.industryDaunorubicinConsolidation ChemotherapyCell BiologyLength of Staymedicine.diseaseSurgeryConsolidation ChemotherapyTransplantationPlatelet transfusionCytarabinebusiness030215 immunologyBlood
researchProduct

Clinical impact of GATA2 mutations in acute myeloid leukemia patients harboring CEBPA mutations: a study of the AML study group.

2016

Clinical impact of GATA2 mutations in acute myeloid leukemia patients harboring CEBPA mutations: a study of the AML study group

AdultMaleCancer Researchmedicine.medical_specialtyMyeloidAdolescentmedicine.disease_causeCohort Studies03 medical and health sciencesYoung Adult0302 clinical medicinehemic and lymphatic diseasesInternal medicineCEBPAmedicineHumansneoplasmsAgedMutationHematologybusiness.industryMyeloid leukemiaHematologyMiddle Agedmedicine.diseaseLymphomaGATA2 Transcription FactorHaematopoiesisLeukemiaLeukemia Myeloid Acutemedicine.anatomical_structureOncology030220 oncology & carcinogenesisMutationCancer researchCCAAT-Enhancer-Binding ProteinsFemalebusiness030215 immunologyLeukemia
researchProduct